Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Kiora Pharmaceuticals, Inc. (KPRX)

3.78   0.1 (2.72%) 12-02 15:44
Open: 3.62 Pre. Close: 3.68
High: 3.805 Low: 3.5801
Volume: 12,528 Market Cap: 4(M)

Technical analysis

as of: 2022-12-02 4:24:09 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 6.83     One year: 8.74
Support: Support1: 3.21    Support2: 2.67
Resistance: Resistance1: 5.85    Resistance2: 7.48
Pivot: 4.47
Moving Average: MA(5): 3.66     MA(20): 4.85
MA(100): 6.79     MA(250): 17.65
MACD: MACD(12,26): -0.9     Signal(9): -0.8
Stochastic oscillator: %K(14,3): 10.7     %D(3): 9.9
RSI: RSI(14): 33
52-week: High: 71.59  Low: 0.37
Average Vol(K): 3-Month: 573 (K)  10-Days: 121 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ KPRX ] has closed above bottom band by 35.1%. Bollinger Bands are 18.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.81 - 3.83 3.83 - 3.85
Low: 3.54 - 3.56 3.56 - 3.58
Close: 3.74 - 3.78 3.78 - 3.81

Company Description

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Headline News

Fri, 18 Nov 2022
Healthcare Stocks on the Move Friday: PXMD, ISEE, CFMS, APLS, SCLX, KPRX, INM, GTHX - InvestorsObserver

Fri, 18 Nov 2022
How Will the Market React to Kiora Pharmaceuticals Inc (KPRX) Stock Getting a Bearish Rating - InvestorsObserver

Fri, 18 Nov 2022
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.59% By Investing.com - Investing.com

Wed, 09 Nov 2022
Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End - Yahoo Finance

Wed, 19 Oct 2022
Kiora Pharmaceuticals Inc (KPRX) Up 4.17% in Premarket Trading - InvestorsObserver

Tue, 04 Oct 2022
Should You Accumulate Kiora Pharmaceuticals Inc (KPRX) Stock Tuesday Morning? - InvestorsObserver

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 1 (M)
Shares Float 1 (M)
% Held by Insiders 11.6 (%)
% Held by Institutions 7.6 (%)
Shares Short 85 (K)
Shares Short P.Month 143 (K)

Stock Financials

EPS -1.78
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.75
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -29.4
Return on Equity (ttm) -124
Qtrly Rev. Growth 0
Gross Profit (p.s.) -4.51
Sales Per Share 0
EBITDA (p.s.) -8.86
Qtrly Earnings Growth 0
Operating Cash Flow -11 (M)
Levered Free Cash Flow -6 (M)

Stock Valuations

PE Ratio -2.14
PEG Ratio 0
Price to Book value 0.38
Price to Sales 0
Price to Cash Flow -0.39

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-08-29
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.